Journal of Blood Disorders & Transfusion

Treatment and survival in patients with chronic myeloid leukemia in chronic phase (CML-CP) in West Iran

4^th International Conference on Blood Malignancies & Treatment

April 18-19, 2016 Dubai, UAE

Mehrdad Payandeh, Masoud Sadeghi and Edris Sadeghi

Kermanshah University of Medical Sciences, Iran

Scientific Tracks Abstracts: J Blood Disord Transfus

Abstract:

CML includes 30% of all leukemias, and occurs from childhood to old age. The present study was a retrospective analysis of chronic phase CML patients registered to Hematology Clinic in Kermanshah, Iran, with checking of treatment options in this disease. Between 2002 and 2014, 85 CML patients referred to Hematology Clinic were selected for our study. We surveyed age, sex, B-symptoms, Splenomegaly, Sokal score, Hasford score, treatment and survival in all patients. Philadelphia chromosome analysis was done for each patient by conventional cytogenetics. We compared treatment in the patients with three drugs (Imatinib, Hydroxyurea (HU) and Interferon alpha (IFN-α)). The mean age of the patients at diagnosis was 47.5±14.5 years (range, 23-82 years), with 43 male patients (50.6%). 13 patients (15.3%) referred to clinic for the first time with B-symptoms and 44 patients (51.8%) had splenomegaly. Sokal score for 77 patients (90.6%) was low, 4 (4.7%) was intermediate and 4 (4.7%) was high, but Hasford (Euro) Score for all patients was low. The 5-year survival rate for treated patients with Imatinib, Imatinib plus HU and Imatinib plus HU plus IFN-α was 90.5%, 81.1% and 55.6%, respectively. The mean age and median age at diagnosis for the patients are around 40-50 years. Also, the results show that Imatinib therapy alone approves survival in CML patients compared to HU or IFN-α. Combination of IFN-α and/or HU with Imatinib probably reduce survival.

Biography :

Mehrdad Payandeh has completed his MD from Kermanshah University of Medical Science (KUMS). He is a Chair of Hemophilia Center of Kermanshah city and Chair of Bone Marrow Transplantation Center of Kermanshah city. He has five years of experience in diagnoses and treatment of hematology, oncology, coagulative, BMT patient's disorder in private and university hospital. He has published more than 70 papers in reputed journals and has been serving as an Editorial Board Member of repute.

Email: md.payandeh@yahoo.com